Harinder Singh1, David R Schulze, Lance R McMahon. 1. Department of Pharmacology, The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
Abstract
RATIONALE: Cannabinoid CB(1) receptor agonists vary in efficacy in vitro; however, relationships between efficacy and behavioral effects are unclear. OBJECTIVE: This study examined the relationship between apparent CB(1) agonist efficacy and in vivo effects. METHODS: Male C57BL/6J mice responded for food under a fixed ratio 30 schedule; rectal temperature was measured. Sensitivity of the mice to cannabinoid agonists (rank order efficacy in vitro reported to be CP 55940 > anandamide > Δ(9)-tetrahydrocannabinol; Δ(9)-THC) and a non-cannabinoid (the benzodiazepine midazolam) was determined before, during, and after discontinuation of daily Δ(9)-THC treatment (32 mg/kg/day, i.p.). Rimonabant was combined with cannabinoids to examine whether CB(1) receptors mediated effects on response rate. RESULTS: Δ(9)-THC, CP 55940, anandamide, and midazolam decreased responding at doses smaller than those producing hypothermia. Rimonabant antagonized the rate-decreasing effects of Δ(9)-THC and CP 55940, but not those of anandamide. Δ(9)-THC treatment produced tolerance for both rate-decreasing and hypothermic effects. Δ(9)-THC treatment did not change sensitivity to the rate-decreasing effects of CP 55940, but produced cross-tolerance to CP 55940 for hypothermic effects. Δ(9)-THC treatment did not modify sensitivity to anandamide and midazolam. CONCLUSIONS: CB(1) receptors mediate the operant rate-decreasing effects of Δ(9)-THC and CP 55940, but not anandamide, in mice. CB(1) agonist efficacy is an important determinant of in vivo effects, especially with regard to the magnitude of tolerance and cross-tolerance resulting from daily Δ(9)-THC treatment. This applies not only to different cannabinoids when measuring the same effect but also to the same cannabinoid when measuring different effects.
RATIONALE: CannabinoidCB(1) receptor agonists vary in efficacy in vitro; however, relationships between efficacy and behavioral effects are unclear. OBJECTIVE: This study examined the relationship between apparent CB(1) agonist efficacy and in vivo effects. METHODS: Male C57BL/6J mice responded for food under a fixed ratio 30 schedule; rectal temperature was measured. Sensitivity of the mice to cannabinoid agonists (rank order efficacy in vitro reported to be CP 55940 > anandamide > Δ(9)-tetrahydrocannabinol; Δ(9)-THC) and a non-cannabinoid (the benzodiazepine midazolam) was determined before, during, and after discontinuation of daily Δ(9)-THC treatment (32 mg/kg/day, i.p.). Rimonabant was combined with cannabinoids to examine whether CB(1) receptors mediated effects on response rate. RESULTS: Δ(9)-THC, CP 55940, anandamide, and midazolam decreased responding at doses smaller than those producing hypothermia. Rimonabant antagonized the rate-decreasing effects of Δ(9)-THC and CP 55940, but not those of anandamide. Δ(9)-THC treatment produced tolerance for both rate-decreasing and hypothermic effects. Δ(9)-THC treatment did not change sensitivity to the rate-decreasing effects of CP 55940, but produced cross-tolerance to CP 55940 for hypothermic effects. Δ(9)-THC treatment did not modify sensitivity to anandamide and midazolam. CONCLUSIONS:CB(1) receptors mediate the operant rate-decreasing effects of Δ(9)-THC and CP 55940, but not anandamide, in mice. CB(1) agonist efficacy is an important determinant of in vivo effects, especially with regard to the magnitude of tolerance and cross-tolerance resulting from daily Δ(9)-THC treatment. This applies not only to different cannabinoids when measuring the same effect but also to the same cannabinoid when measuring different effects.
Authors: A A Coutts; S Anavi-Goffer; R A Ross; D J MacEwan; K Mackie; R G Pertwee; A J Irving Journal: J Neurosci Date: 2001-04-01 Impact factor: 6.167
Authors: B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman Journal: Proc Natl Acad Sci U S A Date: 2001-07-24 Impact factor: 11.205
Authors: Christopher S Breivogel; Susan M Scates; Irina O Beletskaya; Olivia B Lowery; Mario D Aceto; Billy R Martin Journal: Eur J Pharmacol Date: 2003-01-17 Impact factor: 4.432
Authors: S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi Journal: Pharmacol Res Date: 2015-09-08 Impact factor: 7.658
Authors: Torbjörn U C Järbe; Sherrica Tai; Brian J LeMay; Spyros P Nikas; Vidyanand G Shukla; Alexander Zvonok; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2011-10-12 Impact factor: 4.530
Authors: Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather Journal: Pharmacol Res Date: 2017-08-23 Impact factor: 7.658
Authors: Girish R Chopda; Viraj Parge; Ganesh A Thakur; S John Gatley; Alexandros Makriyannis; Carol A Paronis Journal: J Pharmacol Exp Ther Date: 2016-05-26 Impact factor: 4.030
Authors: Brett C Ginsburg; Lenka Hruba; Armia Zaki; Martin A Javors; Lance R McMahon Journal: Drug Alcohol Depend Date: 2014-03-19 Impact factor: 4.492